Effect of Distreptaza® Distrept on the antibiofilm activity of clindamycin against Staphylococcus spp.

Authors

DOI:

https://doi.org/10.18370/2309-4117.2020.56.43-46

Keywords:

biofilms, Staphylococcus spp., Distreptaza® Distrept, antibacterial agents

Abstract

This article highlights one of the most important medical and social problems – an increase in the number of diseases of the female reproductive system caused by microorganisms and the insufficient effectiveness of modern antimicrobial medicines, absence of medicine with antibiofilm action. This prompts the authors to search for products that increase the effectiveness of antibiotic therapy, as well as medicines that can suppress film formation and disrupt the biofilm structure. The article presents the results of studying the biofilms sensitivity formed by Staphylococcus spp. to the action of the enzyme preparation Distreptaza® Distrept and its effect on the specific antibacterial activity of clindamycin.

Purpose of the study: to evaluate the Distreptaza® Distrept impact on the specific effect of clindamycin against the biofilms of Staphylococcus aureus and Staphylococcus epidermidis.

Materials and methods: one-day cultures of S. aureus 222 and S. epidermidis 297 were used in the experiments. Solutions of drugs and microorganisms were added simultaneously, with the action on the formed biofilms – 24 hours after the introduction of the bacterial inoculum to study the effect of medicines on film formation. Experiments were carried out according to the generally accepted technique based on the sorption of gentian violet by biofilm structures with subsequent desorption of the dye into an organic solvent.

Results: the experiments showed that Distreptaza® Distrept interferes with the film formation of Staphylococcus spp. (S. aureus inhibition in 85.4%, S. epidermidis in 20.3%). Distreptaza® Distrept affects the biofilms formed by S. aureus, the biomass of S. aureus decreases by 59.5%. It was found that Distreptaza® Distrept enhances the specific activity of clindamycin, both at the stage of film formation, and on the formed biofilms.

Conclusions: the medicine Distreptaza® Distrept has antibiofilm activity, increases the specific antibacterial effect of clindomycin against biofilms of gram-positive microorganisms. This allows us to talk about the prospects for this drug use as monotherapy in chronic recurrent diseases of the genital tract, as well as in combination with antimicrobial drugs.

Author Biographies

N. O. Vrynchanu, SI “Institute of Pharmacology and Toxicology of the NAMS of Ukraine”

MD, head of the Laboratory of Pharmacology of Antimicrobial Agents

N. I. Hrynchuk, SI “Institute of Pharmacology and Toxicology of the NAMS of Ukraine”

Junior researcher

V. V. Samsonova, SI “Institute of Pharmacology and Toxicology of the NAMS of Ukraine”

General practitioner

References

  1. Rakhmatulina, M.R., Shatalova, A.Y. “Modern concepts of the microbiocenosis of the vaginal biotope and its disorders in women of reproductive age.” Bulletin of Dermatology and Venereology 3 (2009): 38–42.
  2. Paladine, H.L., Desai, U.A. “Vaginitis: Diagnosis and Treatment.” American Family Physician 97.5 (2018).
  3. Prilepskaya, V.N., Abakarova, P.R., Mukhambetalieva, D.D. “Vulvovaginal infections and women's health.” Effective pharmacotherapy 16.7 (2020): 40–6. DOI: 10.33978/2307-3586-2020-16-7-40-46
  4. Chew, S.Y., Than, L.T.L. “Vulvovaginal candidiosis: contemporary challenges and the future of prophylactic and therapeutic approaches.” Mycoses 59.5 (2016): 262–73.
  5. Kosei, N.V. “Modern principles of treatment of inflammatory diseases of female genital organs.” Reproductive endocrinology 1.9 (2013): 78–85. DOI: 10.18370/2309-4117.2013.9.78-85
  6. Khamaganova, I.V. “Nonspecific vulvovaginitis.” Medical advice 14 (2011): 63–8.
  7. Tikhomirov, A.L., Kazenashev, V.V., Sarsania, S.I., Tuskaev, K.S. “Prebiotic correction in bacterial vaginosis.” Medical advice 2 (2017): 66–8.
  8. Chibueze, I.J., Falaki, A.A., Danladi, C.M., et al. “Biofilm formation and antibiotic susceptibility profile of clinical isolates of Staphylococcus aureus isolated from clinical samples in Zaria, Nigeria.” Clinical Microbiology 6 (2017): 295.
  9. Chebotar, I.V., Mayansky, A.N., Mayansky, N.A. “Matrix of microbial biofilms.” Clin Microbiol Antimicrobial chemother 1 (2016): 9–19.
  10. Hogan, S., O'Gara, J.P., O'Neill, E. “Novel treatment of Staphylococcus aureus device-related infections using fibrinolytic agents.” Antimicrobial agents and chemotherapy 62.2 (2018): e02008-17.
  11. Jørgensen, N.P., et al. “Streptokinase treatment reverses biofilm-associated antibiotic resistance in Staphylococcus aureus.” Microorganisms 4.3 (2016): 36.
  12. Kanwar, K., et al. “Enzymes as competent tool for efficient management of pathogen’s biofilms.” Annals of Phytomedicine 8.1 (2019): 70–81.
  13. Sharma, K., Pagedar Singh, A. “Antibiofilm effect of dnase against single and mixed species biofilm.” Foods 7.3 (2018): 42.
  14. O'Toole, G.A. “Microtiter dish biofilm formation assay.” J Vis Exp 47 (2011).
  15. Clindamycin. About drug. Available from: [http://lekmed.ru/lekarstva/sistemnye- antibakterialnye/klindamicin.html].
  16. Hernandez-Bernal, F., Valenzuela-Silva, C.M., et al. “Recombinant streptokinase suppositories in the treatment of acute haemorrhoidal disease. Multicentre randomized double- blind placebo-controlled trial (THERESA-2).” Colorectal Disease 15 (2013): 1423–8.
  17. Hernandez-Bernal, F., Castellanos-Sierra, G., et al. “Recombinant streptokinase vs phenylephrine-based suppositories in acute hemorrhoids, randomized, controlled trial (THERESA-3).” World J Gastroenterol 20.6 (2014): 1594–1601.
  18. Hernandez-Bernal, F., Castellanos-Sierra, G., et al. “Recombinant streptokinase vs hydrocortisone suppositories in acute hemorrhoids: A randomized controlled trial (THERESA-4).” World J Gastroenterol 21.23 (2015): 7305–12.
  19. Zapotoczna, M., O’Neill, E., O'Gara, J.P. “Untangling the Diverse and Redundant Mechanisms of Staphylococcus aureus Biofilm Formation / 3*.” PLOS Pathogens (2016). DOI: 10.1371/journal.ppat.1005671
  20. Carothers, K.E., Liang, Z., Mayfield, J., et al. “The Streptococcal Protease SpeB Antagonizes the Biofilms of the Human Pathogen Staphylococcus aureus USA300 through Cleavage of the Staphylococcal SdrC Protein.” J Bacteriol 202.11 (2020). DOI: 10.1128/JB.00008-20
  21. Kaiyu Zhang, Xin Li, Chen Yu, Yang Wang. “Promising Therapeutic Strategies Against Microbial Biofilm Challenges / 1,2.” Front Cell Infect Microbiol 10 (2020): 359. DOI: 10.3389/fcimb.2020.00359
  22. Shakir, A., et al. “Removal of Biofilms from Tracheoesophageal Speech Valves Using a Novel Marine Microbial Deoxyribonuclease.” Otolaryngology-Head and Neck Surgery 147.3 (2012): 509–14. DOI: 10.1177/0194599812442867
  23. Taylor, P.K., Yeung, A.T.Y., Hancock, R.E.W. “Antibiotic resistance in Pseudomonas aeruginosa biofilms: Towards thedevelopment of novel anti-biofilm therapies.” Journal of Biotechnology 191 (2014): 121–30.
  24. Roya, R., Tiwaria, M., Donelli, G., Tiwaria, V. “Strategies for combating bacterial biofilms: A focus on anti- biofilm agents and their mechanisms of action.” Virulence 9.1 (2018): 522–54. DOI: 10.1080/21505594.2017.1313372
  25. Yanab, J., Bassler, B.L. “Surviving as a community: antibiotic tolerance and persistence in bacterial biofilms.” Cell Host Microbe 26.1 (2019): 15–21. DOI: 10.1016/j.chom.2019.06.002
  26. Tatarchuk, T.F., Kosei, N.V., Zanko, O.V., Yusko, T.I. “Endometrial polyps: optimization of anti-inflammatory therapy.” Reproductive endocrinology 6.44 (2019): 8–14. DOI: 10.18370/2309-4117.2018.44.8-14

Downloads

Published

2020-12-29

How to Cite

Vrynchanu, N. O., Hrynchuk, N. I., & Samsonova, V. V. (2020). Effect of Distreptaza® Distrept on the antibiofilm activity of clindamycin against Staphylococcus spp. REPRODUCTIVE ENDOCRINOLOGY, (56), 43–46. https://doi.org/10.18370/2309-4117.2020.56.43-46

Issue

No. 56 (2020)

Section

Inflammatory diseases

License

Copyright (c) 2020 N. O. Vrynchanu, N. I. Hrynchuk, V. V. Samsonova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.